One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.1200/jco.2014.32.15_suppl.tps3114
Copy DOI Journal: Journal of Clinical Oncology |  Publication Date: May 20, 2014 |
 Citations: 10 |
Affiliation: Memorial Sloan Kettering Cancer Center, Levine Cancer Institute, Emory University, The University of Texas MD Anderson Cancer Center, National Center for Tumor Diseases, Oregon Health & Science University, Vanderbilt University, Sarah Cannon, Royal Marsden NHS Foundation Trust, Dana-Farber Cancer Institute, Harvard University, Bristol-Myers Squibb (United States), Duke Medical Center, Moffitt Cancer Center, Sidney Kimmel Comprehensive Cancer Center, Helsinki University Hospital, Beatson West of Scotland Cancer Centre, University of GlasgowTPS3114 Background: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, and ipilimumab, a fully human IgG1 cytotoxic T-lymphocyte antigen-4 receptor (CTLA-...
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
